| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
IC50: 2.9 nM (α5β1)[1]
c(phg-isoDGR-(NMe)k) TFA targets the alpha5beta1-integrin, a cell surface receptor that mediates cell adhesion to fibronectin and is involved in cell migration, proliferation, and survival. It is a selective and potent ligand for this integrin with an IC₅0 of 2.9 nM. The cyclic peptide's isoDGR motif mimics the RGD sequence found in natural integrin ligands such as fibronectin, allowing high-affinity binding. In vivo, it is trimerized with the chelator TRAP and used as a PET tracer. |
|---|---|
| ln Vitro |
In vitro, c(phg-isoDGR-(NMe)k) TFA is a selective and potent ligand for alpha5beta1-integrin with an IC₅0 of 2.9 nM. This binding affinity is typically assessed using solid-phase binding assays or surface plasmon resonance. The cyclic peptide's activity includes competitive inhibition of natural ligands (like fibronectin) for binding to the alpha5beta1 integrin. It is not typically used in cell viability assays, as it is a ligand for studying integrin expression rather than a modulator of cell growth.
|
| ln Vivo |
c(phg-isoDGR-(NMe)k) TFA is employed as a positron-emission tomography tracer to track the expression of α5β1 integrin in an M21 mouse xenograft after being trimerized with the chelator TRAP[1].
In vivo, c(phg-isoDGR-(NMe)k) TFA is trimerized with the chelator TRAP (triazacyclononane-triphosphinate) and used as a positron-emission tomography (PET) tracer for monitoring alpha5beta1 integrin expression in M21 mouse xenograft models. The tracer allows non-invasive imaging of integrin expression, which is upregulated in tumor angiogenesis and metastasis. The specific activity of the tracer is detailed in published research studies. |
| Enzyme Assay |
Binding of c(phg-isoDGR-(NMe)k) TFA to alpha5beta1-integrin is assessed using non-cellular solid-phase binding assays or surface plasmon resonance (SPR). In a solid-phase binding assay, purified alpha5beta1-integrin is immobilized on a microplate. Various concentrations of the peptide are incubated with the integrin in the presence of a labeled competitive ligand. After washing, bound peptide is detected, and the IC₅0 (2.9 nM) is calculated from a competition curve. SPR can provide real-time binding kinetics.
|
| Cell Assay |
Cellular assays for c(phg-isoDGR-(NMe)k) TFA are performed using alpha5beta1 integrin-expressing cell lines, such as M21 melanoma cells or U87 glioblastoma cells. Cells are incubated with the peptide (which may be labeled with a fluorophore or radionuclide). Binding is assessed by flow cytometry or by measuring radioactivity. The ability of the peptide to inhibit cell adhesion to fibronectin-coated plates can also be measured, with cells pre-treated with the peptide before seeding on fibronectin; after washing, adherent cells are quantified by staining with crystal violet.
|
| Animal Protocol |
In vivo animal studies are performed using mouse xenograft models of cancer. For PET imaging studies, c(phg-isoDGR-(NMe)k) is trimerized with the chelator TRAP and labeled with a positron-emitting radionuclide (e.g., ⁶⁸Ga). The tracer is injected intravenously into mice bearing M21 (alpha5beta1-positive) or control tumors. PET/CT imaging is performed at various time points post-injection (e.g., 30, 60, 120 minutes). Tumor uptake is quantified as %ID/g (percent injected dose per gram) and compared to blocking studies with excess unlabeled peptide to confirm specificity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for c(phg-isoDGR-(NMe)k) TFA are not detailed in standard product literature. As a cyclic peptide, it has improved metabolic stability compared to linear peptides. When trimerized with the TRAP chelator for in vivo imaging, the conjugate exhibits favorable pharmacokinetic properties for tumor targeting, including rapid blood clearance and high tumor-to-background ratio. The specific PK parameters are reported in specialized imaging literature.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for c(phg-isoDGR-(NMe)k) TFA are not provided in standard product literature. As a research-use cyclic peptide, standard safety assessments for acute toxicity, genotoxicity, and organ-specific toxicity are not typically described. For laboratory use, standard chemical safety precautions for handling peptides should be followed. The compound is for research use only and not for diagnostic or therapeutic human use.
|
| References | |
| Additional Infomation |
c(phg-isoDGR-(NMe)k) TFA has the molecular formula C2₉H42F3N₉O₉ and a molecular weight of 717.69. It appears as a solid at room temperature. The compound is stored at -20degC, sealed, and away from moisture. The peptide incorporates the isoDGR motif (isomer of the RGD sequence) which is known for its selective affinity to alpha5beta1 integrin over other integrin subtypes. It is trimerized with the chelator TRAP for PET imaging applications. The product is for research use only.
|
| Molecular Formula |
C29H42F3N9O9
|
|---|---|
| Molecular Weight |
717.69
|
| Exact Mass |
717.306
|
| Related CAS # |
c(phg-isoDGR-(NMe)k);1844830-65-4
|
| PubChem CID |
145712309
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
9
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
50
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CN1[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC(=O)NCC(=O)N[C@H](C1=O)CCCN=C(N)N)C(=O)O)C2=CC=CC=C2)CCCCN.C(=O)(C(F)(F)F)O
|
| InChi Key |
ILAYWYHCAONWQF-DIKLDQRVSA-N
|
| InChi Code |
InChI=1S/C27H41N9O7.C2HF3O2/c1-36-19(11-5-6-12-28)23(39)35-22(16-8-3-2-4-9-16)24(40)34-18(26(42)43)14-20(37)32-15-21(38)33-17(25(36)41)10-7-13-31-27(29)30;3-2(4,5)1(6)7/h2-4,8-9,17-19,22H,5-7,10-15,28H2,1H3,(H,32,37)(H,33,38)(H,34,40)(H,35,39)(H,42,43)(H4,29,30,31);(H,6,7)/t17-,18-,19+,22+;/m0./s1
|
| Chemical Name |
(5S,8R,11R,14S)-8-(4-aminobutyl)-5-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,16-pentaoxo-11-phenyl-1,4,7,10,13-pentazacyclohexadecane-14-carboxylic acid;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~250 mg/mL (~348.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3934 mL | 6.9668 mL | 13.9336 mL | |
| 5 mM | 0.2787 mL | 1.3934 mL | 2.7867 mL | |
| 10 mM | 0.1393 mL | 0.6967 mL | 1.3934 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
